PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab.

@article{Jensen2012PIK3CAMP,
  title={PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab.},
  author={Jeanette Dupont Jensen and As Knoop and A. V. Laenkholm and Morten Grauslund and M B Jensen and Eric Santoni-Rugiu and Michael Andersson and Marianne Ewertz},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2012},
  volume={23 8},
  pages={2034-42}
}
BACKGROUND This study was conducted to determine the frequency of PIK3CA mutations and human epidermal growth factor receptor-2 (HER2) phosphorylation status (pHER2-Tyr1221/1222) and if PIK3CA, phosphatase and tensin homolog (PTEN), or pHER2 has an impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab. PATIENTS AND METHODS Two hundred and forty HER2-positive early-stage breast cancer patients receiving adjuvant treatment… CONTINUE READING
Highly Influential
This paper has highly influenced 10 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS
56 Citations
62 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 56 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 62 references

Similar Papers

Loading similar papers…